Tandem Diabetes Care, Inc. reported earnings results for the third quarter and nine months ended September 30, 2023. For the third quarter, the company reported sales was USD 185.62 million compared to USD 204.55 million a year ago. Net loss was USD 32.96 million compared to USD 48.97 million a year ago. Basic loss per share from continuing operations was USD 0.51 compared to USD 0.76 a year ago. Diluted loss per share from continuing operations was USD 0.51 compared to USD 0.76 a year ago.
For the nine months, sales was USD 550.92 million compared to USD 580.72 million a year ago. Net loss was USD 192.61 million compared to USD 78.74 million a year ago. Basic loss per share from continuing operations was USD 2.97 compared to USD 1.23 a year ago. Diluted loss per share from continuing operations was USD 2.97 compared to USD 1.23 a year ago.